Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)-Reference-Cited by-同舟云学术

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Published:2017-10 Issue:10105 Volume:390 Page:1853-1862
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Schachter Jacob,Ribas Antoni,Long Georgina V,Arance Ana,Grob Jean-Jacques,Mortier Laurent,Daud Adil,Carlino Matteo S,McNeil Catriona,Lotem Michal,Larkin James,Lorigan Paul,Neyns Bart,Blank Christian,Petrella Teresa M,Hamid Omid,Zhou Honghong,Ebbinghaus Scot,Ibrahim Nageatte,Robert Caroline

Publisher

Elsevier BV

Subject

General Medicine

Reference34 articles.

1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

2. Yervoy [package insert],2015

3. Keytruda [package insert],2016

4. Opdivo [package insert],2016

5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 1020 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Updates on CAR T cell therapy in multiple myeloma;Biomarker Research;2024-09-12

3. Long-Term Results of Treatment of Patients with Stage IV Malignant Melanoma in the Sverdlovsk Region;Ural Medical Journal;2024-09-03

4. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial;British Journal of Cancer;2024-08-20

5. Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy;Bulletin of Mathematical Biology;2024-08-07